This Open Access volume provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases. Antimicrobial resistance (AMR) is widely recognized to be one of the greatest threats to global public health in coming decades; and it has thus become a major topic of discussion among leading bioethicists and scholars from related disciplines including economics, epidemiology, law, and political theory. Topics covered in this volume include responsible use of antimicrobials; control of multi-resistant hospital-acquired infections; privacy and data collection; antibiotic use in childhood and at the end of life; agricultural and veterinary sources of resistance; resistant HIV, tuberculosis, and malaria; mandatory treatment; and trade-offs between current and future generations. As the first book focused on ethical issues associated with drug resistance, it makes a timely contribution to debates regarding practice and policy that are of crucial importance to global public health in the 21st century.

Natural Polysaccharides in Drug Delivery and Biomedical Applications provides a fundamental overview of natural polysaccharides, their sources, extraction methodologies, and characterizations. It covers specific natural polysaccharides and their effective application in drug delivery and biomedical use. Additionally, chapters in the book discuss key topics including the sources and extraction methodologies of natural polysaccharides, their role in tissue engineering applications, polysaccharide-based nanoparticles in biomedical applications, and their role in the delivery of anticancer drugs. Written by industry leaders and edited by experts, this book emphasizes recent advances made in the field. Natural Polysaccharides in Drug Delivery and Biomedical Applications provides academics, researchers, and pharmaceutical health care professionals with a comprehensive book on polysaccharides in pharmaceutical delivery process.

The purpose of this book is to provide a broad scope of substance use disorder research and how these findings can impact treatment outcomes. The research and outcomes described in this book represent important principles related to identifying and understanding factors related to substance use disorders. The first section is dedicated to methodology including population-based surveys, basic neuroanatomy, chemistry, molecular biology, behavioral models and brain imaging. The second section utilizes this methodology in research related to opioids, cocaine, marijuana, alcohol and nicotine. The book is aimed at both professionals (academics, clinicians, practitioners) and students or trainees.

Nervous System Drug Delivery: Principles and Practice helps users understand the nervous system physiology affecting drug delivery, the principles that underlie various drug delivery methods, and the appropriate application of drug delivery methods for drug- and disease-specific treatments. Researchers developing nervous system putative therapeutic agents will use this book to optimize drug delivery during preclinical assessment and to prepare for regulatory advancement of new agents. Clinicians will gain direct insights into pathophysiologic alterations that impact drug delivery and students and trainees will find this a critical resource for understanding and applying nervous system drug delivery techniques.

Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders. Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans.

Blockbuster drugs-each of which generates more than a billion dollars a year in revenue-have revolutionized the industry since the early 1980s, when sales of Tagamet alone transformed a minor Philadelphia-based firm into the world's ninth-largest pharmaceutical company. In Blockbuster Drugs, Jie Jack Li tells the fascinating stories behind the discovery and development of these highly lucrative medicines, while also exploring the tumult the industry now faces as the "patent cliff" nears. Having spent most of his career in drug research and development, Li brings an insider's eye to the narrative as he recounts the tales of discovery behind such drugs as Tagamet, Zantac, Claritin, Prilosec, Nexium, Serouquel, Plavix, and Ambien. As he discusses each breakthrough, Li also shows that scientific research is filled with human drama-serendipitous discoveries, sudden insights, tense confrontations. For instance, the author tells of James Black, who persisted in the research that led to Tagamet-and that would ultimately win him a Nobel Prize-despite pressure from top executives to pursue "more profitable" work. The book shows how research behind Prilosec combined creativity, international cooperation, and luck-the turning point being a chance encounter of American and Swedish scientists at a conference in Uppsala. There are also tales of fabulous rewards-George Rieveschl, the chemist who invented Benadryl, made a fortune on royalties-and of unjust desserts. Finally, Li shows that for the world's largest prescription drug manufacturers, recent years have been harrowing, as many popular drugs have come off patent in the U.S. market, meaning hundreds of billions of dollars in lost revenue. Anyone who enjoys tales of scientific discovery, or is curious about the history behind the prescriptions they take, or wants a revealing inside look at the pharmaceutical industry will find this book well worth reading.

This innovative edited collection brings together leading international academics to explore the use of various non-prescription and prescription substances. From a psychosocial perspective, the authors discuss the complex reasons behind their adoption, the ways in which they are misused, and links between use and cognitive enhancement. While studies on substance use to date have examined the aetiology and effects in the context of sporting performance, addiction and recreational use, there has been little work which explores their wider misuse to improve cognitive enhancement. With medical sociology and social psychology at its core, this important volume shows the complex reasons behind the misuse of various substances, how these are connected to contemporary desire for increased mental performance, and why the potential health risks and possibly harmful side effects do not act as deterrents.

The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industrys productivity problems and address important global health care and economic issues. This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes.

NETosis: Immunity, Pathogenesis and Therapeutics takes a focused approach to the clinical aspects of NETosis and drug development, bringing critical findings. Chapters introduce NETosis, consider mechanisms and antimicrobial strategies regulating NETosis, examine NETosis in neonates, explore the role of NETosis in autoimmunity, delve into NETosis and other diseases, and present therapeutic approaches for dysregulated NETosis. Since Brinkamm, et al, discovered an unrecognized neutrophil anti-microbial mechanism responsible for the extracellular killing of invading pathogens in 2004, the novel process in which nuclear chromatin de-condenses and DNA is ejected into the extra cellular environment, trapping and inactivating tissue pathogens has rapidly evolved.

This issue of Clinics in Chest Medicine, edited by Dr. Denis O'Donnell and Dr. Alberto Neder, focuses on Clinical Respiratory Physiology. Articles include: The Pathophysiology of Obstructive Sleep Apnea; The Physiology of Mechanical Ventilation; Exercise Pathophysiology in Congestive Heart Failure; Control of Breathing; Breathing at Extremes; Exercise Pathophysiology in Interstitial Lung Disease; Importance of Physiology in Clinical Decision-Making in the ICU; Pulmonary Hypertension and Exercise; Physiologic Effects of Oxygen Supplementation During Exercise in COPD; Benefits and Pitfalls of DLCO measurements in Clinical Practice; Cardio-pulmonary Interactions in COPD-CHF; Exercise Physiology in COPD; Dyspnea of Unknown Origin: The Role of Exercise Testing; Assessment of Ventilatory Limitation During Exercise; Respiratory Muscle Assessment in Clinical Practice; Exertional Periodic Breathing in Heart Failure; and Strategies to Increase Physical Activity in Chronic Respiratory Diseases.

This book offers an in indictment of the nation's drug enforcement approach focusing on the short-sighted policies that often deny patients suffering from chronic pain the medications they need. Pain Control and Drug Policy: A Time for Change focuses on America's national crisis in pain management caused by the widening divergence between the enormous contributions of opioids ("narcotics") to pain management in the clinical setting and the mistaken belief that they are dangerous, highly addictive drugs. After dissecting the strategy and tactics of the War on Drugs from medical, historical, legal, socioeconomic, and geopolitical perspectives, Guy Faguet MD indicts the 40-year-long War on Drugs for having failed to stem the supply of illicit drugs in America despite expenditures of half a trillion dollars, despite violating the basic human right to pain relief of tens of millions of American chronic pain sufferers, and despite fomenting organized crime, government corruption, racial injustice, and social disruption in both the United States and the producer countries. He concludes with a clarion call for the abandonment of the War on Drugs, disbanding the Drug Enforcement Administration, and encouraging Congress to repeal the Controlled Substances Act. As a clinical and research oncologist responsible for the chronic pain management of thousands of cancer patients over the course of his 30-year career, Dr. Faguet knows that the most effective and safest way to manage most cases of chronic pain is with opioids. All modern pain-management textbooks advocate "titration to effect" in cases where opioids help: that is, gradually increasing the dosage until either the pain is acceptably controlled or the side effects begin to outweigh the pain-relief benefits. Yet the vast majority of doctors don't practice what the medical textbooks teach and instead prescribe opioids very reluctantly and conservatively. As a result, only half of all chronic pain sufferers-and fewer than half of all cancer patients-get adequate pain relief from their doctors. Why do physicians radically undertreat pain that is susceptible to opioid analgesics? They fear that if they prescribe Schedule II opioids in accordance with the professional standards of pain management set by such medical bodies as the American Pain Society, they will be investigated by the DEA, stigmatized, prosecuted as criminals, stripped of their licenses, and sent to jail. Visit Guy B. Faguet, MD's website here: www.faguet.net.

This book provides a comprehensive, organized, and concise overview of xenobiotic metabolic enzymes and their health implications. The subjects addressed are broad in scope with an emphasis on recent advances in research on biochemical and biomedical aspects of these enzymes. The xenobiotics discussed include not just drugs, but also food, smoke, and other environmental chemicals. The subjects covered in this work include: metabolic enzymes and their catalyzed reactions, reactive intermediates generated from metabolic activation, oxidative stress mediated by electrophilic reactive intermediates, bioactivation - mediated cellular and functional damages, activation of Nrf2 - ARE pathway, genetic variations affecting metabolic enzyme expression, enzyme polymorphisms affecting xenobiotic - mediated toxicity, induction of metabolic enzymes for health benefits, and a diversity of metabolic enzyme modulators.

This book sheds light on the major functions of microbial communities in aquaculture ecosystems, showing that by recycling nutrients, degrading organic matter and preventing disease outbreaks, a variety of microbes are truly beneficial to a wide range of aquaculture industries. It discusses how deteriorating environmental quality enables some microbial strains to trigger disease, describes the development of highly sustainable tools to improve water quality, and identifies crucial factors that endanger microbial homeostasis in aquaculture ecosystems. The book also covers post-antibiotic approaches for preventing and treating opportunistic microbial infections based on harnessing environmental and fish-associated microbial communities. Furthermore, it explores how manipulating and engineering these complex microbial communities using bio-agents such as probiotics, phages, natural nutritional additives, or with fine-tuned biofilters will open the door for new ways to develop a more sustainable and cost-effective aquaculture industry. Including an accessible presentation of modern high-throughput sequencing technology to identify host-microbial interactions in aquaculture ecosystems, this book is a valuable resource for scientists, aquaculture and fishery experts, sustainability enthusiasts and scholars in the areas of biology and marine agriculture.

"Pharmaceutical Pharmacology", encompassing 78 chapters, is divided into four major comprehensive parts. Part A deals with general pharmacology, pharmacology of peripheral nervous system and pharmacology of central nervous system. Part B is concerned with pharmacology of cardiovascular system, drugs acting on the hemopoetic system, drugs acting on the urinary system, autocoids and drugs acting on the respiratory system. Part C contains chapters on drugs acting on the gastrointestinal tract, pharmacology of endocrine system, chemotherapy and principles of toxicology. Part D discusses mainly clinical pharmacy, pharmacotherapy, important disorders of organ system and their management, therapeutic drug monitoring and concept of essential drugs and rational drug use.To provide a realistic approach to the understanding of the subject, each chapter commences with a crisp introduction followed by classification, treatment of each class of drugs with reference to important 'drugs' vis-a-vis pharmacological actions, pharmacokinetic actions, mechanism of action, therapeutic uses, dosage regimens, adverse drug reactions, drug interaction, etc. The text is profusely illustrated with labelled diagrams, graphics and lucid explanations. It provides the reader an explicit route starting from the molecular understanding of receptors and drug activities to the therapeutic applications of the most important class of drugs.